{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.2"},{"groupId":"OG001","value":"0.9"}]}],"title":"Complete response rate"},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.5"},{"groupId":"OG001","value":"18.8"}]}],"title":"Partial response rate"}],"denoms":[{"counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"112"}],"units":"Participants"}],"description":"Overall Clinicohematologic Response is defined as any participant who achieved a complete or partial clinicohematologic response per the European LeukemiaNet modified criteria for response in polycythemia vera (PV). A Complete Response (CR) is defined as: hematocrit control, spleen volume reduction at least 35% from baseline, platelet count less than or equal to 400 x 10(9)/L, and white blood cell count less than or equal to 10 x 10(9)/L. A Partial Response (PR) is defined as hematocrit control or response in all 3 of the other criteria.","groups":[{"description":"Starting dose of 10 mg BID with individualized dose titration ranging from 5 mg QD to 25 mg BID based on safety and efficacy","id":"OG000","title":"Ruxolitinib"},{"description":"Best Available Therapy (BAT) will be selected by the Investigator for each participant. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements.","id":"OG001","title":"Best Available Therapy"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS) comprises all participants to whom study treatment had been assigned by randomization.","reportingStatus":"POSTED","timeFrame":"32 Weeks","title":"The Percentage of Participants Who Achieved Overall Clinicohematologic Response at Week 32","type":"SECONDARY","unitOfMeasure":"percentage of participants"}